UNLABELLED: High rates of pertussis disease in adolescents suggest that additional boosting against pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine (dTpa-IPV; Boostrixtrade mark Polio, n =440) was compared to separately administered dTpa (Boostrixtrade mark) and inactivated polio virus (IPV; Imovax Polio((R)), n =219), and to DTPa-IPV (Infanrixtrade mark IPV, n =111) vaccine in a partially blind, randomised controlled trial in 10-14 year olds. One month after vaccination, seroprotection/seropositivity rates for all antigens were similar for all groups. Although pertussis and diphtheria antibody geometric mean antibody concentrations were higher after DTPa-IPV, all subjects had protective antibodies against diphtheria, tetanus and polio, and at least 97% had a vaccine response to pertussis antigens. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV, but dTpa-IPV was generally better tolerated than DTPa-IPV. CONCLUSION: The combined reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine is immunogenic and well tolerated when administered to adolescents and could be used to improve the control of pertussis disease in this age group.
RCT Entities:
UNLABELLED: High rates of pertussis disease in adolescents suggest that additional boosting against pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine (dTpa-IPV; Boostrixtrade mark Polio, n =440) was compared to separately administered dTpa (Boostrixtrade mark) and inactivated polio virus (IPV; Imovax Polio((R)), n =219), and to DTPa-IPV (Infanrixtrade mark IPV, n =111) vaccine in a partially blind, randomised controlled trial in 10-14 year olds. One month after vaccination, seroprotection/seropositivity rates for all antigens were similar for all groups. Although pertussis and diphtheria antibody geometric mean antibody concentrations were higher after DTPa-IPV, all subjects had protective antibodies against diphtheria, tetanus and polio, and at least 97% had a vaccine response to pertussis antigens. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV, but dTpa-IPV was generally better tolerated than DTPa-IPV. CONCLUSION: The combined reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine is immunogenic and well tolerated when administered to adolescents and could be used to improve the control of pertussis disease in this age group.
Authors: M E Pichichero; M A Deloria; M B Rennels; E L Anderson; K M Edwards; M D Decker; J A Englund; M C Steinhoff; A Deforest; B D Meade Journal: Pediatrics Date: 1997-11 Impact factor: 7.124
Authors: M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp Journal: Vaccine Date: 2001-12-12 Impact factor: 3.641
Authors: Danuta M Skowronski; Gaston De Serres; Diane MacDonald; Wrency Wu; Carol Shaw; Jane Macnabb; Sylvie Champagne; David M Patrick; Scott A Halperin Journal: J Infect Dis Date: 2002-04-22 Impact factor: 5.226
Authors: Ming Lin; Paul Roche; Jenean Spencer; Alison Milton; Phil Wright; David Witteveen; Robyn Leader; Angela Merianos; Chris Bunn; Heather Gidding; John Kaldor; Martyn Kirk; Rob Hall; Tony Della-Porta Journal: Commun Dis Intell Q Rep Date: 2002
Authors: Line M Lindgren; Pernille N Tingskov; Annette H Justesen; Bettina S Nedergaard; Klaus J Olsen; Lars V Andreasen; Ingrid Kromann; Charlotte Sørensen; Jes Dietrich; Birgit Thierry-Carstensen Journal: Vaccine Date: 2016-12-24 Impact factor: 3.641